Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q4 2025 value amounting to -$940000.0.

  • Agios Pharmaceuticals' Gains from Investment Securities fell 10214.68% to -$940000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $628000.0, marking a year-over-year decrease of 9854.46%. This contributed to the annual value of $628000.0 for FY2025, which is 9854.46% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Gains from Investment Securities stood at -$940000.0 for Q4 2025, which was down 10214.68% from $65000.0 recorded in Q3 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Gains from Investment Securities peaked at $43.8 million during Q4 2024, and registered a low of -$8.3 million during Q4 2021.
  • Over the past 5 years, Agios Pharmaceuticals' median Gains from Investment Securities value was $83500.0 (recorded in 2022), while the average stood at $2.3 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Gains from Investment Securities plummeted by 979534.88% in 2021, and later skyrocketed by 25767058.82% in 2024.
  • Agios Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$8.3 million in 2021, then soared by 101.0% to $83000.0 in 2022, then crashed by 120.48% to -$17000.0 in 2023, then surged by 257670.59% to $43.8 million in 2024, then tumbled by 102.15% to -$940000.0 in 2025.
  • Its Gains from Investment Securities was -$940000.0 in Q4 2025, compared to $65000.0 in Q3 2025 and $1.3 million in Q2 2025.